Ardelyx vs Arcutis Biotherapeutics
ARDX and ARQT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ARDX and ARQT compare
Arcutis Biotherapeutics is the larger company, worth 4.6 times as much as Ardelyx ($3.6B against $770M).
Arcutis Biotherapeutics grew revenue faster over the last twelve months (60.0% versus 16.8% for Ardelyx).
Arcutis Biotherapeutics keeps more of each dollar of sales as profit, with a net margin of 5.9% compared with −12.4% at Ardelyx.
Arcutis Biotherapeutics scores higher on the StockData Score (11 against 9 for Ardelyx), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ARDX | ARQT |
|---|---|---|
| Size and price | ||
| Market cap | $770M | $3.6B |
| Share price | $3.09 | $28.26 |
| Change, 1 year | −48.8% | 20.5% |
| Change, 5 years | 209% | 55.4% |
| Beta (5Y) | 0.95 | 0.92 |
| Employees | 489 | 354 |
| StockData Score | ||
| Total score | 9 | 11 (better) |
| Valuation score | 2 (better) | 0 |
| Growth score | 3 | 4 (better) |
| Performance score | 3 | 4 (better) |
| Health score | 1 | 3 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 128× |
| P/S | 1.7× (better) | 7.0× |
| P/B | 5.2× (better) | 14.6× |
| EV/EBITDA | – | 96.7× |
| P/FCF | – | 59.5× |
| FCF yield | −2.3% | 1.7% (better) |
| Fair value | $7.50 | $6.04 |
| Margin of safety | 58.8% (better) | −368% |
| Growth | ||
| Revenue growth (TTM) | 16.8% | 60.0% (better) |
| Revenue growth, 5Y average | 122% | – |
| Profitability | ||
| Gross margin | 94.4% (better) | 91.2% |
| Operating margin | −7.9% | 6.9% (better) |
| Net margin | −12.4% | 5.9% (better) |
| FCF margin | −4.0% | 11.7% (better) |
| Return on equity | −38.6% | 14.9% (better) |
| Return on invested capital | – | 32.9% |
| Financial health | ||
| Debt / equity | – | 0.45 |
| Net debt / EBITDA | – | −4.27 |
| Interest coverage | −1.6× | 2.6× (better) |
| Current ratio | 3.34 (better) | 2.92 |
| Altman Z-score | −0.13 | 6.54 (better) |
| Piotroski F-score | 3 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 71.2% | 105% |
| Held by insiders | 6.9% | 9.3% |
| Insider net buying, 12 months | −$1.9M (better) | −$11.1M |
| Short interest, % of float | 12.6% | 15.9% |
Go deeper
- ARDX stock overview
- ARDX income statement
- ARDX valuation and score
- ARQT stock overview
- ARQT income statement
- ARQT valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.